Solubility-Aware Protein Binding Peptide Design Using AlphaFold
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
New protein–protein interactions (PPIs) are identified, but PPIs have different physicochemical properties compared with conventional targets, making it difficult to use small molecules. Peptides offer a new modality to target PPIs, but designing appropriate peptide sequences by computation is challenging. Recently, AlphaFold and RoseTTAFold have made it possible to predict protein structures from amino acid sequences with ultra-high accuracy, enabling de novo protein design. We designed peptides likely to have PPI as the target protein using the “binder hallucination” protocol of AfDesign, a de novo protein design method using AlphaFold. However, the solubility of the peptides tended to be low. Therefore, we designed a solubility loss function using solubility indices for amino acids and developed a solubility-aware AfDesign binder hallucination protocol. The peptide solubility in sequences designed using the new protocol increased with the weight of the solubility loss function; moreover, they captured the characteristics of the solubility indices. Moreover, the new protocol sequences tended to have higher affinity than random or single residue substitution sequences when evaluated by docking binding affinity. Our approach shows that it is possible to design peptide sequences that can bind to the interface of PPI while controlling solubility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
ColabFold - Making protein folding accessible to all
Mirdita, M., Schütze, K., Moriwaki, Y., Heo, L., Ovchinnikov, S., & Steinegger, M. (2021) · doi:10.1101/2021.08.15.456425 · Cited by 9,391
Accurate prediction of protein structures and interactions using a 3-track network
Baek, M., DiMaio, F., Anishchenko, I., Dauparas, J., Ovchinnikov, S., Lee, G. R., Wang, J., Cong, Q., Kinch, L. N., Schaeffer, R. D., et al. (2021) · doi:10.1101/2021.06.14.448402 · Cited by 5,549 · cited 1×
“Recently, protein structure prediction using deep neural networks, which estimate 3D structures from the co-evolution of amino acid residues, has been widely used [29,30].”
BackgroundTherapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Oughtred, R., Rust, J., Chang, C., Breitkreutz, B., Stark, C., Willems, A., Boucher, L., Leung, G., Kolas, N., Zhang, F., et al. (2021) · Protein Science · doi:10.1002/pro.3978 · Cited by 1,858 · cited 1×
“Approximately 810,000 human non-redundant PPIs have been identified [2] (BioGrid 4.”
BackgroundSmall-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Harnessing protein folding neural networks for peptide–protein docking
Tsaban, T., Varga, J. K., Avraham, O., Ben-Aharon, Z., Khramushin, A., & Schueler-Furman, O. (2022) · Nature Communications · doi:10.1038/s41467-021-27838-9 · Cited by 1,205
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891 · cited 1×
“Antibodies are an effective modality for recognizing PPI interfaces; although they are effective for targeting receptors on the cell membrane surface, they are not effective against intracellular PPI targets because they have difficulty penetrating the cell membrane [16].”
BackgroundDe novo protein design by deep network hallucination
Anishchenko, I., Chidyausiku, T. M., Ovchinnikov, S., Pellock, S. J., & Baker, D. (2020) · doi:10.1101/2020.07.22.211482 · Cited by 629 · cited 2×
“AfDesign is a public module created by Dr. Sergey Ovchinnikov [36], and it is a tool for designing protein-binding peptides based on Dr. Sergey’s previous work with trRosetta [33,50].”
BackgroundMethodDesign of protein-binding proteins from the target structure alone
Cao, L., Coventry, B., Goreshnik, I., Huang, B., Sheffler, W., Park, J. S., Jude, K. M., Marković, I., Kadam, R. U., Verschueren, K. H. G., et al. (2022) · Nature · doi:10.1038/s41586-022-04654-9 · Cited by 577
Research works printed but not linked: 34
- Bonetta, 2010, Interactome under Construction, Nature, 468, 851, 10.1038/468851a · DOI · Paper page
- Toogood, 2002, Inhibition of Protein-Protein Association by Small Molecules: Approaches and Progress, J. Med. Chem., 45, 1543, 10.1021/jm010468s · DOI · Paper page
- Dev, 2004, Making protein interactions druggable: Targeting PDZ domains, Nat. Rev. Drug Discov., 3, 1047, 10.1038/nrd1578 · DOI · Paper page
- Souers, 2013, ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets, Nat. Med., 19, 202, 10.1038/nm.3048 · DOI · Paper page
- Shin, 2020, Current challenges and opportunities in designing protein–protein interaction targeted drugs, Adv. Appl. Bioinform. Chem., 13, 11
- Truong, 2021, Analysis of Physicochemical Properties of Protein–Protein Interaction Modulators Suggests Stronger Alignment with the “Rule of Five”, RSC Med. Chem., 12, 1731, 10.1039/D1MD00213A · DOI
- Kosugi, T., and Ohue, M. (2021). Quantitative Estimate Index for Early-Stage Screening of Compounds Targeting Protein-Protein Interactions. Int. J. Mol. Sci., 22. · DOI
- Wodak, 2002, Structural Basis of Macromolecular Recognition, Adv. Protein Chem., 61, 9, 10.1016/S0065-3233(02)61001-0 · DOI · Paper page
- Conte, 1999, The Atomic Structure of Protein-Protein Recognition Sites11Edited by A. R. Fersht, J. Mol. Biol., 285, 2177, 10.1006/jmbi.1998.2439 · DOI · Paper page
- Smith, 2012, Features of Protein–Protein Interactions That Translate into Potent Inhibitors: Topology, Surface Area and Affinity, Expert Rev. Mol. Med., 14, e16, 10.1017/erm.2012.10 · DOI · Paper page
- Wells, 2007, Reaching for High-Hanging Fruit in Drug Discovery at Protein–Protein Interfaces, Nature, 450, 1001, 10.1038/nature06526 · DOI · Paper page
- Cabri, 2021, Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives, Front. Mol. Biosci., 8, 565, 10.3389/fmolb.2021.697586 · DOI · Paper page
- Wu, 2016, Advancement and Applications of Peptide Phage Display Technology in Biomedical Science, J. Biomed. Sci., 23, 8, 10.1186/s12929-016-0223-x · DOI · Paper page
- Nemoto, 1997, In Vitro Virus: Bonding of MRNA Bearing Puromycin at the 3′-Terminal End to the C-Terminal End of Its Encoded Protein on the Ribosome in Vitro, FEBS Lett., 414, 405, 10.1016/S0014-5793(97)01026-0 · DOI · Paper page
- Roberts, 1997, RNA-Peptide Fusions for the in Vitro Selection of Peptides And Proteins, Proc. Natl. Acad. Sci. USA, 94, 12297, 10.1073/pnas.94.23.12297 · DOI · Paper page
- Das, 2021, Accelerated Antimicrobial Discovery via Deep Generative Models and Molecular Dynamics Simulations, Nat. Biomed. Eng., 5, 613, 10.1038/s41551-021-00689-x · DOI · Paper page
- Cardoso, 2020, Computer-Aided Design of Antimicrobial Peptides: Are We Generating Effective Drug Candidates?, Front. Microbiol., 10, 3097, 10.3389/fmicb.2019.03097 · DOI · Paper page
- Capecchi, 2020, Populating Chemical Space with Peptides Using a Genetic Algorithm, J. Chem. Inf. Model., 60, 121, 10.1021/acs.jcim.9b01014 · DOI
- Baran, 2017, Principles for Computational Design of Binding Antibodies, Proc. Natl. Acad. Sci. USA, 114, 10900, 10.1073/pnas.1707171114 · DOI · Paper page
- Gulsevin, A., and Meiler, J. (2022). Benchmarking Peptide Structure Prediction with AlphaFold2. bioRxiv. · DOI
- Fosgerau, 2015, Peptide Therapeutics: Current Status and Future Directions, Drug Discov., 20, 122
- Esposito, 2006, Enhancement of Soluble Protein Expression through the Use of Fusion Tags, Curr. Opin. Biotechnol., 17, 353, 10.1016/j.copbio.2006.06.003 · DOI · Paper page
- Wu, 2010, Structure-Based Engineering of a Monoclonal Antibody for Improved Solubility, Protein Eng. Des. Sel., 23, 643, 10.1093/protein/gzq037 · DOI · Paper page
- Mant, 2009, Intrinsic Amino Acid Side-Chain Hydrophilicity/Hydrophobicity Coefficients Determined by Reversed-Phase High-Performance Liquid Chromatography of Model Peptides: Comparison with Other Hydrophilicity/Hydrophobicity Scales, Pept. Sci., 92, 573, 10.1002/bip.21316 · DOI
- Argos, 1982, Structural Prediction of Membrane-Bound Proteins, Eur. J. Biochem., 128, 565, 10.1111/j.1432-1033.1982.tb07002.x · DOI · Paper page
- Kyte, 1982, A Simple Method for Displaying the Hydropathic Character of a Protein, J. Mol. Biol., 157, 105, 10.1016/0022-2836(82)90515-0 · DOI · Paper page
- Zhang, 2019, AutoDock CrankPep: Combining Folding and Docking to Predict Protein–Peptide Complexes, Bioinformatics, 35, 5121, 10.1093/bioinformatics/btz459 · DOI · Paper page
- Word, 1999, Asparagine and Glutamine: Using Hydrogen Atom Contacts in the Choice of Side-Chain Amide Orientation, J. Mol. Biol., 285, 1735, 10.1006/jmbi.1998.2401 · DOI · Paper page
- Morris, 2009, AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility, J. Comput. Chem., 30, 2785, 10.1002/jcc.21256 · DOI · Paper page
- Crooks, 2004, WebLogo: A Sequence Logo Generator, Genome Res., 14, 1188, 10.1101/gr.849004 · DOI · Paper page
- Chang, L., and Perez, A. (2022). AlphaFold Encodes the Principles to Identify High Affinity Peptide Binders. bioRxiv. · DOI
- Adasme, 2021, PLIP 2021: Expanding the Scope of the Protein-Ligand Interaction Profiler to DNA and RNA, Nucleic Acids Res., 49, W530, 10.1093/nar/gkab294 · DOI · Paper page
- Weng, 2020, Comprehensive Evaluation of Fourteen Docking Programs on Protein–Peptide Complexes, J. Chem. Theory Comput., 16, 3959, 10.1021/acs.jctc.9b01208 · DOI · Paper page
- Shin, 2017, In Silico Structure-Based Approaches to Discover Protein-Protein Interaction-Targeting Drugs, Methods, 131, 22, 10.1016/j.ymeth.2017.08.006 · DOI · Paper page
Cited by
Design of Cyclic Peptides Targeting Protein–Protein Interactions Using AlphaFold
(2023) · doi:10.3390/ijms241713257 · Cited by 51
Zhang, C., Xu, Z., Lin, K., Zhu, N., Zhang, C., Xu, W., Guo, J., Su, A., Li, C., & Duan, H. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00227 · Cited by 12
Limitations of the refolding pipeline for de novo protein design
Korbeld, K. T., Viliuga, V., & Fürst, M. J. L. J. (2026) · Protein Science · doi:10.1002/pro.70613 · Cited by 5
Metadata
- Authors
- Kosugi, T., & Ohue, M.
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2022-07-07
- Volume
- 10
- Issue
- 7
- Pages
- 1626
- ISSN
- 2227-9059 (ISSN-L)
- OpenAlex
- W4284710673
- Cited by
- 31
- References
- 19
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Japan Science and Technology Agency (JST) FOREST (JPMJFR216J, JPMJAX20A3, 20H04280, JP22ama121026)
- JST ACT-X (JPMJFR216J, JPMJAX20A3, 20H04280, JP22ama121026)
- Japan Society for the Promotion of Science (JSPS) KAKENHI (JPMJFR216J, JPMJAX20A3, 20H04280, JP22ama121026)
- Japan Agency for Medical Research and Development (AMED) Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS) (JPMJFR216J, JPMJAX20A3, 20H04280, JP22ama121026)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Solubility-Aware Protein Binding Peptide Design Using AlphaFold. https://app.cochat.ai/papers/10.3390/biomedicines10071626
- The paper
- Kosugi, T., & Ohue, M. (2022). Solubility-Aware Protein Binding Peptide Design Using AlphaFold. Biomedicines. https://doi.org/10.3390/biomedicines10071626
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.